{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:54:31Z","timestamp":1788155671428,"version":"build-2803163510"},"reference-count":44,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["pathsocjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pathology CR"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CD74 is a type II transmembrane glycoprotein that functions as an MHC class II chaperone and displays diverse roles in immune responses. Recently, anti\u2010CD74 immunotherapy has shown promise as an effective treatment strategy for lymphoid neoplasms in preclinical models. Using a human anti\u2010CD74 antibody (SP7219), we defined the expression of CD74 protein in both normal and over 790 neoplastic hematolymphoid tissue samples. We found that CD74 is expressed broadly in normal B\u2010cell compartments including primary and secondary lymphoid follicles and in the thymic medulla. The vast majority of lymphomas expressed CD74, including Hodgkin lymphomas (98%), B\u2010cell lymphomas (96%), extranodal NK\/T\u2010cell lymphomas (88%), mature T\u2010cell lymphomas (80%), and plasma cell myeloma (75%). Our findings confirm and expand previous observations regarding the expression of CD74 and suggest that CD74 expression on tumor cells may be directly targeted for immunomodulatory therapy for lymphoid and plasma cell malignancies.<\/jats:p>","DOI":"10.1002\/cjp2.114","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T04:39:27Z","timestamp":1536295167000},"page":"12-24","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["High frequency of CD74 expression in lymphomas: implications for targeted therapy using a novel anti\u2010CD74\u2010drug conjugate"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0562-6817","authenticated-orcid":false,"given":"Shuchun","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Pathology Stanford University School of Medicine  Stanford CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Molina","sequence":"additional","affiliation":[{"name":"Sutro Biopharma  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Yu","sequence":"additional","affiliation":[{"name":"Sutro Biopharma  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Hanson","sequence":"additional","affiliation":[{"name":"Sutro Biopharma  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Cheung","sequence":"additional","affiliation":[{"name":"Sutro Biopharma  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Li","sequence":"additional","affiliation":[{"name":"Sutro Biopharma  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasodha","family":"Natkunam","sequence":"additional","affiliation":[{"name":"Department of Pathology Stanford University School of Medicine  Stanford CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.154.1.137"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1167"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.133.2.1028"},{"key":"e_1_2_6_5_1","first-page":"225","article-title":"Detailed phenotypic analysis of B\u2010cell lymphoma using a panel of antibodies reactive in routinely fixed wax\u2010embedded tissue","volume":"128","author":"Norton AJ","year":"1987","journal-title":"Am J Pathol"},{"key":"e_1_2_6_6_1","first-page":"29","article-title":"Monoclonal antibodies marking B\u2010cell non\u2010Hodgkin's lymphoma in paraffin\u2010embedded tissue","volume":"1","author":"Linder J","year":"1988","journal-title":"Mod Pathol"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198809000-00006"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/95.4.517"},{"key":"e_1_2_6_9_1","first-page":"19","article-title":"Bauhinia purpurea\u2010a new paraffin section marker for Reed\u2010Sternberg cells of Hodgkin's disease. A comparison with Leu\u2010M1 (CD15), LN2 (CD74), peanut agglutinin, and Ber\u2010H2 (CD30)","volume":"141","author":"Sarker AB","year":"1992","journal-title":"Am J Pathol"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(01)00503-1"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64120-X"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199601000-00007"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00022744-200009000-00007"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4334"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2010.08.013"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2016.03.026"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00115"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-016-0995-1"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2015.08.005"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.142"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1028052"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-720342"},{"key":"e_1_2_6_23_1","first-page":"573","article-title":"High frequency of CD74 expression in B\u2010cell non\u2010Hodgkin's lymphoma (NHL) and targeting with STRO\u2010001, a novel anti\u2010CD74 antibody drug conjugate (ADC) with potent in vitro Cytotoxicty and in vivo anti\u2010tumor activity","volume":"130","author":"Yu A","year":"2017","journal-title":"Blood"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzu002"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.4.2.19202"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc400490z"},{"key":"e_1_2_6_27_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2017"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkm861"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2005.06.013"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-255067"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-011-0189-5"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-112128"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1841"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031074"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.565437"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0182"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1095"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.11.3289"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0904149"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204641"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.060632"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09837"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.07.003"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.07.004"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-243535"}],"container-title":["The Journal of Pathology: Clinical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcjp2.114","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pathsocjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cjp2.114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:32:32Z","timestamp":1760265152000},"score":1,"resource":{"primary":{"URL":"https:\/\/pathsocjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cjp2.114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1002\/cjp2.114"],"URL":"https:\/\/doi.org\/10.1002\/cjp2.114","archive":["Portico"],"relation":{},"ISSN":["2056-4538","2056-4538"],"issn-type":[{"value":"2056-4538","type":"print"},{"value":"2056-4538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,8]]},"assertion":[{"value":"2018-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}